Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
- #Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: gene.com/media/press-re…
- #Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-re…
- #Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: gene.com/media/press-re…
- #Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: gene.com/media/press-re…

